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This review is focused on advances in understanding the biology of joint homeostasis and osteoarthritis
(OA) pathogenesis mechanisms that have led to proof of concept studies on new therapeutic approaches.
The three selected topics include angiogenesis in joint tissues, biomechanics and joint lubrication and
mitochondrial dysfunction. This new information represents progress in the integration of mechanisms
that control multiple aspects of OA pathophysiology.
 2011 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
The osteoarthritis (OA) disease process affects all joint tissues,
leading to joint dysfunction and pain and systemic and organismal
changes that reduce quality of life, initiate or aggravate
co-morbidities and reduce life expectancy. Progress in under-
standing the biology of joint homeostasis and disease mechanisms
is essential for the development of new approaches to prevent or
treat OA. To cover the general topic ‘biology’ assigned to this review,
areas of biology that are most relevant to OA were considered.
These include developmental biology of joints and joint tissues,
stem cell biology, cell and molecular biology of adult joint tissue
homeostasis, mechanobiology, extracellular matrix biology,
systems biology and the biology of aging. These areas of biology
provide a knowledge base for research on the pathobiology of OA.
OA biology can also be viewed on the basis of scale, ranging from
molecular to cellular, tissue, organ and organism level processes
that determine risk for onset and progression of the disease or are
affected by the disease process.
As an in depth review of all areas of biology is not possible
within this manuscript, three ﬁelds, angiogenesis, joint lubrica-
tion and mitochondrial homeostasis were selected for detailed
review to illustrate how progress in biology has led to identiﬁ-
cation and preclinical validation of new targets for the treatment
of OA.to: M. Lotz, The Scripps
Jolla, CA 92037, United States.
s Research Society International. PAngiogenesis
The formation of new blood vessels has previously been
recognized as essential for the development of synovial hyper-
plasia1 in arthritic joints where the synovial membrane becomes
thickened, from increased proliferation of synovial ﬁbroblasts,
which also deposit new extracellular matrix. The formation of new
blood vessels that supply oxygen and nutrients is not only neces-
sary for the development of the hyperplastic synovium but also
leads to tissue inﬁltration with blood-derived inﬂammatory cells
and mediators. Synovial angiogenesis has been studied extensively
in rheumatoid arthritis (RA). Many studies on angiogenesis
compared RA, OA and normal synovium and the general conclusion
is that angiogenesis correlates with the extent of synovial hyper-
plasia, which is most severe in RA, but also present in OA-affected
joints2. The prominent role of synovial hyperplasia in RA has led to
studies targeting mediators of angiogenesis such as vascular
endothelial growth factor (VEGF) and this has been successful in RA
animal models3.
The importance of angiogenesis in OA is further supported by
recent observations that new blood vessels are not only formed in
synovium but also in other tissues. Normal articular cartilage is
avascular, and this has been related to the presence of angiogenesis
inhibitors, such as thrombospondin, chondromodulin4, and
collagen XVIII-derived endostatin5. OA articular cartilage is invaded
at the osteochondral junction by blood vessels from the sub-
chondral bone, which leads to increased blood vessel density in the
non-calciﬁed cartilage6. The osteochondral angiogenesis is also
associated with subchondral bone marrow replacement by ﬁbro-
vascular tissue expressing VEGF, and with increased nerve growth
factor (NGF) expression within vascular channels that containublished by Elsevier Ltd. All rights reserved.
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observed in menisci along the ﬁbrocartilage junction with
increased penetration into the inner region7. These new blood
vessels are also surrounded by sensory nerve ﬁbers. The anterior
cruciate ligaments from OA-affected human joints show increased
numbers of blood vessels in the synovial sheath and within the
ligament substance, where the new blood vessels are surrounded
by cell aggregates8. Blood vessels and nerves also penetrate newly
formed cartilage in osteophytes at the joint margins9.
OA joints contain increased levels of VEGF in articular cartilage
and synovial ﬂuid and several cytokines that stimulate VEGF
production are present10,11. The increased VEGF production in OA
has also been linked to the shift in hypoxia inducible factors and the
abnormal hypertrophic differentiation of OA chondrocytes12.
Growth plate chondrocyte hypertrophy physiologically generates
angiogenic factors to initiate vascular invasion of the hypertrophic
zone13.
This new information that neovascularization is a feature of
several tissues in OA joints and the association of angiogenesis with
increased new sensory nerve ﬁber formation supports the
hypothesis that these processes contribute to both structural
change and pain in OA14. To test this hypothesis in the rat menis-
cectomy model of OA, PPI-2458, a speciﬁc inhibitor of endothelial
cell proliferation was administered. PPI-2458 reduced synovial and
osteochondral angiogenesis, synovial inﬂammation, cartilage
damage and osteophyte formation. Importantly, this treatment also
reduced pain behavior14. This study was the ﬁrst to establish
simultaneous beneﬁt of an angiogenesis inhibitor on structure and
pain modiﬁcation in an OA model.
Several previous studies support angiogenesis inhibition as
a promising approach for OA. Adenovirus-mediated thrombo-
spondin-1 gene transfer in an OA model in rats signiﬁcantly
reduced microvessel density, inﬂammation, and suppressed
OA progression15. The limitation of this study was that
thrombospondin-1 has activities in addition to inhibition of
angiogenesis that may contribute to the observed effects. In
a cartilage repair model, the use of stem cells that overexpressed
the VEGF antagonist sFlt-1 reduced angiogenesis and improved
new cartilage tissue formation without osteophyte development16.
Angiogenesis inhibition through chondromodulin prevented
chondrocyte hypertrophy and stabilized the articular chondrocyte
phenotype17.
Collectively, these new observations motivate further studies on
the use of more speciﬁc and potent angiogenesis inhibitors in OA to
better understand interactions between angiogenesis, cartilage and
bone remodeling and pain mechanisms. The availability of anti-
angiogenic drugs that are approved for certain types of cancer and
eye diseases18 facilitates clinical evaluation of this approach in OA.
The mitochondria-autophagy connection
Much of the progress in understanding OA pathogenesis is
related to mechanisms that are activated in established disease.
More recent efforts are directed at deﬁning early changes that
predispose or lead to the onset of OA19. As the majority patients
develop OA as a function of increasing age, it is essential to
understand aging-related changes in cell function. The phenom-
enon of cell aging includes reduced cell proliferation and extra-
cellular matrix synthesis and increased production of reactive
oxygen species (ROS), inﬂammatory mediators and extracellular
matrix degrading enzymes20. This altered pattern of gene and
mediator expression has been designated as the senescence-
associated phenotype21.
Two major mechanisms, telomere and mitochondrial dysfunc-
tion contribute to cellular aging and senescence. Shortening oftelomeres in highly proliferative organs activates p53-dependent
growth arrest, senescence and apoptosis22. Tissues with lower
cell proliferation rates such as muscle or cartilage are equally
affected by the aging process, largely through ROS induced geno-
toxic stress. A new model, which links telomere shortening, p53
activation and mitochondrial dysfunction was proposed in 2011.
According to this model, the telomere-p53 axis suppresses perox-
isome proliferator activated receptor gamma coactivator (PGC)-1a
or PGC-1b, which are the master regulators of mitochondrial
biogenesis and metabolism and this leads to deﬁcient adenosine
triphosphate (ATP) production and increased ROS generation,
contributing to abnormal gene expression and cell death23,24.
Mitochondria also have an important role in pro-inﬂammatory
signaling, as they initiate formation of inﬂammasomes and acti-
vation of other inﬂammatory pathways25.
A series of prior studies demonstrated mitochondrial dysfunc-
tion in various OA models and in human OA. In addition, mito-
chondrial DNA mutations are increased in OA chondrocytes26.
During the past year, new insight was provided on genetic risk
factors and mechanisms of mitochondrial dysfunction, and defects
in the protection against and removal of abnormal mitochondria
in OA.
Rego-Perez et al. had previously reported that mitochondrial
DNA haplogroups contribute to OA risk as disease prevalence in
haplogroup Hwas signiﬁcantly higher compared to haplogroup J. In
their recent study, they showed that serum levels of matrix
metalloproteinase (MMP-13) were signiﬁcantly higher in patients
with OA, and carriers of haplogroup H27. These observations
provide further support for a genetic risk factor that canmanifest as
mitochondrial dysfunction.
Scott et al. analyzed expression of all three forms of superoxide
dismutase, enzymes that protect against ROS-mediated cell
damage. The expression of these three enzymes was down-
regulated in cartilage from human OA joints and guinea pigs with
spontaneous OA. In particular, the mitochondrial superoxide
dismutase (SOD2) was reduced and the decline in SOD2 preceded
OA-like lesions in the animal model28.
The principal mechanism for removal of dysfunctional mito-
chondria is autophagy, or speciﬁcally, mitophagy29. Autophagy is
mediated by formation of double-membrane vesicles, termed
autophagosomes that sequester organelles, proteins, or portions of
the cytoplasm. Autophagosomes then fuse with lysosomes, the
sequestered contents are degraded by lysosomal enzymes and
recycled as a source of energy30.
Autophagy is compromised in OA cartilage and this is in part
related to reduced expression of autophagy regulators31. New
observations by Terkeltaub et al. indicate that AMP-activated
protein kinase (AMPK), which is a key regulator of autophagy
activation under conditions of low energy or other stress conditions
is reduced in OA cartilage and in chondrocytes following treatment
with Interleukin (IL)-1b or Tumor necrosis factor (TNF)a. AMPK
activators attenuate dephosphorylation of AMPKa and procatabolic
responses in chondrocytes induced by these cytokines32.
The scenario suggested by these new observations is that
mitochondrial DNA haplotype H, acquired mitochondrial DNA
mutations and the telomere-p53-PGC1 pathway contribute to
mitochondrial dysfunction, which is further aggravated by deﬁcient
anti-oxidant defenses and impaired autophagy (Fig. 1). Addressing
this pathwaywith anti-oxidants is a feasible and effective approach
in preclinical models33. An alternative approach would be removal
of dysfunctional mitochondria by enhancing autophagy. A target for
enhancing autophagy is the enzyme mammalian target of rapa-
mycin (mTOR), which is the key upstream regulator of autophagy.
ActivatedmTOR prevents autophagy activation and its inhibition by
rapamycin induces autophagy34. In genetically heterogeneous
Fig. 1. Dysfunctional mitochondria in OA pathogenesis. Multiple factors contribute to
mitochondrial dysfunction, including inhibition of mitochondrial biogenesis through
suppression of key mitochondrial transcription factors PGC. Risk for mitochondrial
dysfunction is also increased in individuals with certain mitochondrial DNA haplotypes
and through acquired mitochondrial DNA mutations. As a result of defective auto-
phagy, dysfunctional mitochondria accumulate and produce increased amounts of
ROS, which promote inﬂammatory responses, abnormal gene expression and cell
death. The impact of mitochondrial dysfunction is further aggravated by reduced levels
of SOD2 and deﬁcient anti-oxidant defenses.
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initiated late in life, providing further support for the importance of
autophagy in aging35,36.
In articular cartilage, autophagy is not only deﬁcient in aging31
but also in response to mechanical injury37. In an in vitro model,
rapamycin treatment of cartilage explants that were exposed to
high levels of mechanical load reduced cell death and extracellular
matrix damage37. Rapamycin also suppressed biochemically
induced cell death and nitric oxide production in response to pro-
inﬂammatory cytokines. The ﬁrst study to address potential ther-
apeutic beneﬁts of rapamycin in vivo used a knee instability-
induced OA model in mice. Rapamycin treatment reduced the
severity of OA and this was associatedwith preservation of cartilage
cellularity38. These ﬁndings are the ﬁrst to suggest that rapamycin
is a promising new approach towards chondroprotection. Addi-
tional studies are required to directly link the rapamycin effects to
removal of dysfunctional mitochondria and to analyze its efﬁcacy in
models of aging-related OA.Chondroprotection through lubrication
Articular cartilage functions as a surface that allows joint
movement under conditions of extremely low friction. Hyaluronic
acid (HA) and lubricin are two major joint lubricants and effective
“boundary lubricants” that exhibit low friction and protect surfaces
from wear39. Detailed mechanisms how HA is anchored and
immobilized at the cartilage surface had not been established.
Lubricin adsorbs to various types of substrates and forms
complexes with itself and HA. Lubricin is thus expected to form
cross-links with the surface-immobilized, partially entangled HA
layer forming a cross-linked HA-lubricin complex. However, as the
physical bond between HA and lubricin is relatively weak, it would
be expected to dissociate under normal friction and shear forces40.
The study by Greene et al. examined mechanisms related to low
friction and wear protection. Their results support a new concept of
an adaptive mechanically controlled lubrication mechanism.
According to this model, compression causes diffusion of nominally
free HA out of the cartilage but then becomes physically trapped atthe interface by the increasingly constricted collagen pore network.
The mechanically trapped HA-lubricin complex now acts as an
effective chemically bound lubricant, reducing the friction force
slightly, but more importantly, eliminating wear damage to the
cartilage surfaces. This concept illustrates that the lubrication
system as a whole requires both HA and lubricin to function
optimally.
Besides their role in lubrication, both lubricin and HA have
additional functions in the joint. Lubricin regulates synovial cell
adhesion and proliferation. Lubricin mutations are linked to the
camptodactyly-arthropathy-coxavara-pericarditis syndrome,which
features synovial hyperplasia and failure of joint function41.Mice that
are deﬁcient in lubricin not only show degradation of the cartilage
superﬁcial zone but also hyperplasia of intimal cells in the synovium.
Puriﬁed or recombinant lubricin inhibits the synoviocyte prolifera-
tion invitro42. Interestingly, a splice formof lubricin is a growth factor
for endothelial cells43. Future studies will need to deﬁne in more
detail the lubricin splice forms, their receptors and activities on cells
involved in OA. A large number of studies already reported on
cellular effects of HA, which include anti-inﬂammatory, cytopro-
tective and anabolic activities that are mediated by cell surface
receptors CD44 and receptor for hyaluronan-mediated motility
(RHAMM)44,45.
Both, HA and lubricin are deﬁcient in arthritic joints39. Lubricin
may be degraded and synthesis appears to be reduced, due to loss
of joint lining cells, which are the main producers or due to inhi-
bition of synthesis by inﬂammatory cytokines.
Based on the protective functions of HA and lubricin, their
deﬁciency in arthritis joints and their synergistic activities, recent
studies examined these molecules individually and in combination
in animal models of joint injury and OA. Flannery et al. reported
that intraarticular injection of recombinant lubricin protected
against cartilage degradation in a rat model of OA induced menis-
cectomy andmedial collateral ligament transection46. Jay et al. used
the anterior cruciate ligament transection model in rats to compare
three forms of lubricin, recombinant human lubricin, synovial ﬂuid
lubricin and lubricin produced by cultured synoviocytes47. Injected
lubricin bound to the cartilage surface. All three forms of lubricin
reduced the severity of cartilage damage but only the effect of
lubricin from synoviocytes was statistically signiﬁcant. Lubricin
also protected against glycosaminoglycan depletion, collagen
degradation and loss of cells in the cartilage superﬁcial zone47.
Teeple et al. used the same OAmodel in rats to test lubricin puriﬁed
from human synovial ﬂuid and also compared it to and combined it
with HA. These results conﬁrmed the protective effect of lubricin
but HA did not have protective effects and the therapeutic beneﬁt of
lubricinwas enhanced by the addition of exogenous HA48. Previous
studies on HA effects in OAmodels showed variable results, ranging
from protective to deleterious effects48.
These studies shed new light on the role of joint lubricants as
potential OA therapies. The potential synergy between HA and
lubricin suggested bymolecular models has yet to be demonstrated
in animal models. A speciﬁc clinical indication that appears to
represent a promising opportunity for lubricants as therapeutics in
posttraumatic arthritis, which is associated with an acute deﬁ-
ciency of lubricants49.
Conclusions
These selected examples illustrate how progress in speciﬁc areas
of biology can lead to identiﬁcation of OA therapeutic targets,
which can be readily validated in animal models. The ﬁndings from
the past year add to an extensive list of OA drug candidates that
were effective in animal models. A similar review in 2010 high-
lighted other signaling pathways in aging and the role of abnormal
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how to select among these pathways and molecules the most
promising candidates for testing in clinical trials. The three exam-
ples discussed above represent distinct aspects of OA pathogenesis.
Similarly diverse were the pathways that have been targeted in
completed clinical trials, including inhibitors of matrix degrading
enzymes, bone resorption or IL-1. Clinical trails with these drugs
either failed to show conclusive efﬁcacy or were associated with
adverse events51,52.
These clinical results raise important questions in OA biology.
Are drug targets valid and can methods be developed, for example
based on systems biology approaches, to select or discover more
promising drug targets? Do currently used animal models provide
ameaningful representation of human OA? Are clinical trials design
parameters in regard to patient risk factor proﬁle and stage in the
disease process appropriate? Can stages in the disease process and
corresponding stage-speciﬁc interventions be identiﬁed? Should
OA prevention and treatment start much earlier in the disease
process than in previous studies? Answering these questions
remains a challenge in OA biology and a prerequisite for the ﬁrst
successful clinical trial on a disease-modifying OA drug.
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